NCT04795492

Brief Summary

The study was a multicenter, two-arm, parallel, open-label, prospective clinical trial that evaluated a remote intervention with 1 year of follow-up.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 12, 2021

Completed
20 days until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2023

Completed
Last Updated

February 8, 2024

Status Verified

February 1, 2024

Enrollment Period

2 years

First QC Date

March 9, 2021

Last Update Submit

February 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Medication adherence

    Compliance and administration of cardiovascular protective drugs

    1 year

Secondary Outcomes (12)

  • Blood Pressure

    1 year

  • Body Mass Index

    1 year

  • LDL Cholesterol

    1 year

  • HbA1c

    1 year

  • Smoking

    1 year

  • +7 more secondary outcomes

Study Arms (2)

Intervention group

EXPERIMENTAL

Remote intervention

Behavioral: remote intervention

Control group

ACTIVE COMPARATOR

Routine outpatient follow-up

Behavioral: Routine outpatient follow-up

Interventions

Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.

Intervention group

Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.

Control group

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged between 18-99 years
  • Diagnosed with SCAD according to guidelines by coronary CTA or coronary angiography (including stable angina, ischemic cardiomyopathy, and the stable course after acute coronary syndrome)
  • Have sufficient Chinese language proficiency to reading, speaking and listening
  • Live with at least one caregiver or guardian in the household
  • Presence of stable hemodynamics without using vasopressor
  • Able to individually consent
  • Not participating in any other clinical trial

You may not qualify if:

  • Unable to provide informed consent
  • Unable to be involved in clinical follow-up and treatment
  • Suffered comorbidity with a life expectancy of less than 1 year
  • Have contra-indication to cardiac rehabilitation
  • Acute coronary syndrome
  • History of noncompliance with medical therapy
  • Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial
  • Planned major surgery necessitating interruption of antiplatelet therapy
  • Inability to comply with the protocol
  • Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the subject or that could prevent, limit or confound the protocol-specified assessments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fuwai Hospital, Chinese Academy of Medical Science; National Center for Cardiovascular Diseases

Beijing, Beijing Municipality, 100000, China

Location

Related Publications (3)

  • Zheng X, Spatz ES, Bai X, Huo X, Ding Q, Horak P, Wu X, Guan W, Chow CK, Yan X, Sun Y, Wang X, Zhang H, Liu J, Li J, Li X, Spertus JA, Masoudi FA, Krumholz HM. Effect of Text Messaging on Risk Factor Management in Patients With Coronary Heart Disease: The CHAT Randomized Clinical Trial. Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005616. doi: 10.1161/CIRCOUTCOMES.119.005616.

    PMID: 30998400BACKGROUND
  • Yu C, Liu C, Du J, Liu H, Zhang H, Zhao Y, Yang L, Li X, Li J, Wang J, Wang H, Liu Z, Rao C, Zheng Z; MISSION-2 Collaborative Group. Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization. Am Heart J. 2020 Oct;228:17-26. doi: 10.1016/j.ahj.2020.06.019. Epub 2020 Jul 4.

    PMID: 32745732BACKGROUND
  • Chen X, Zhou X, Li H, Li J, Jiang H. The value of WeChat application in chronic diseases management in China. Comput Methods Programs Biomed. 2020 Nov;196:105710. doi: 10.1016/j.cmpb.2020.105710. Epub 2020 Aug 14.

    PMID: 32858284BACKGROUND

MeSH Terms

Conditions

Angina, StableMyocardial IschemiaCoronary Artery DiseaseHeart Diseases

Condition Hierarchy (Ancestors)

Angina PectorisCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsCoronary DiseaseArteriosclerosisArterial Occlusive Diseases

Study Officials

  • Weihua Song, MD

    Fuwai Hospital, Chinese Academy of Medical Science; National Center for Cardiovascular Diseases

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 9, 2021

First Posted

March 12, 2021

Study Start

April 1, 2021

Primary Completion

April 1, 2023

Study Completion

April 1, 2023

Last Updated

February 8, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations